Henlius’ Trastuzumab Approved In China

Becomes First China-Developed mAb Biosimilar Approved In Both China And EU

 
• By Dave Wallace

Shanghai Henlius Biotech has received the first Chinese approval for a trastuzumab biosimilar version of Herceptin.

Chinese - EU flags
Henlius’ trastuzumab biosimilar has been approved in both China and the EU • Source: Shutterstock

More from Biosimilars

More from Products